Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

AXS-12 Novel Therapy Discovered for the Treatment of Narcolepsy

Axsome Therapeutics, Inc discovered AXS-12 novel therapy for the treatment of cataplexy in patients with narcolepsy. AXS-12 is an oral, highly selective and potent norepinephrine reuptake inhibitor.

AXS-12, developed for cataplexy highlights its potential and provides meaningful benefit and substantial improvement for patients over currently available treatment options living with this debilitating condition. In addition, AXS-12 promotes wakefulness, maintain muscle tone and enhance cognition.

Narcolepsy can be a serious and debilitating neurological condition that causes dysregulation of the sleep-wake cycle and is characterized clinically by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis, and disrupted nocturnal sleep. It is estimated that 185,000 individuals in the U.S. are affected with Narcolepsy. Cataplexy is seen in an estimated 70% of narcolepsy patients and is a sudden reduction or loss of muscle tone while a patient is awake, typically triggered by strong emotions such as laughter, fear, anger, stress, or excitement.

US Food and Drug Administration (FDA) grants Breakthrough Therapy Designation for AXS-12 for the treatment of cataplexy in patients with narcolepsy.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024